Quell Therapeutics
↗London, United Kingdom
Quell Therapeutics is a clinical-stage biotechnology company pioneering the development of engineered T-regulatory (Treg) cell therapies for immune-mediated diseases. The company aims to harness the immune-suppressive properties of Tregs to induce durable immune tolerance, potentially eliminating the need for lifelong immunosuppressive medication in transplant recipients and patients with autoimmune disorders.
Quell's platform utilizes its proprietary Foxp3 Phenotype Lock™ technology, which 'locks' Tregs into a stable, suppressive phenotype to ensure potency and persistence. The company was founded in 2019 by leading experts from University College London (UCL), King's College London, and Hannover Medical School, and is backed by a strong syndicate of life science investors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:N/A (Pre-revenue)
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$344M
Investors:Syncona, Fidelity Management & Research Company, Ridgeback Capital, Jeito Capital, SV Health Investors, AstraZeneca, British Patient Capital, Janus Henderson Investors
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 1/2
Modalities:Cell therapy, CAR-Treg, Engineered Tregs
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (Strategic collaboration for T1D and IBD worth up to $2B+), eXmoor Pharma (Strategic manufacturing partnership for autologous CAR-Tregs), Cellistic (Collaboration for iPSC-derived allogeneic Treg platform)
COMPETITION
Position:Leader
Competitors:GentiBio, Sonoma Biotherapeutics, Sangamo Therapeutics, Kyverna Therapeutics, Sana Biotechnology
LEADERSHIP
Key Executives:
Iain McGill - CEO
Luke Henry - Chief Business Officer
Nathalie Belmonte - SVP Research & Translation
Scientific Founders:Prof. Giovanna Lombardi, Prof. Alberto Sanchez-Fueyo, Prof. Hans Stauss, Prof. Emma Morris, Dr. Marc Martinez-Llordella, Prof. Elmar Jaeckel
Board Members:Luke Beshar (Chair), Dame Kate Bingham, Dhaval Patel, Elisa Petris, Tyrell J. Rivers
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Quell Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.